Allen Baharaff | President, Chief Executive Officer |
Yohai Stenzler | Chief Financial Officer |
Liat Hayardeny | Chief Scientific Officer |
Edward Nash | Canaccord Genuity |
Kristen Kluska | Cantor Fitzgerald |
Timur Ivannikov | Raymond James |
Good day and welcome to Galmed conference call to discuss financial results for the second quarter 2021. Today's conference is being recorded.
Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events. These statements are based on the beliefs and the expectations of the management of today and actual results, trends, timelines or projections in relation to our financial position and projected development program and pipeline could differ materially. We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitation, the risks under the heading Risk Factors described in our Annual Report on Form 20-F filed with the SEC and the risks and uncertainties included in the Form 6 K.